Generative AI for Drug Discovery: Making Medicine Faster

Using generative AI for drug discovery can help make developing pharmaceutical medicine faster, easier, and cheaper, getting people the medicine they need.

Artificial intelligence is the current dominant trend in the tech industry, able to sift through colossal amounts of data to develop new insights and conclusions. This capability makes it enormously appealing to the pharmaceutical industry, which is now exploring generative AI for drug discovery.

How Generative AI Can Be Used in Drug Discovery
It would be impossible to discover, create, and test every single drug-like molecule in existence, considering there are over ten to the sixtieth power of them. Even developing one new drug can cost billions and take decades.

Generative AI can cut through these time and costs, helping create new drugs faster and more affordably. The primary applications for generative AI in drug discovery include:

Molecule Generation
Generative AI can simulate molecular structures and how they interact with a patient's body. Pharmaceutical companies can use this to simulate molecules with desirable properties that are also safe to use inside a patient's body.

Antibody Design
Generative AI can be trained on protein sequences and used to create specific antibodies that target specific pathogens. These protein language models can improve the quality and speed of antibody design, and even develop antibodies that are “zero-shot,” meaning they are created without any training data of antibodies known to bind to those specific targets.

Drug Repurposing
By reviewing existing scientific knowledge and documentation with AI, pharmaceutical companies can discover new uses for drugs already approved for public use. This helps companies avoid the typical development costs associated with discovery. For example, the drug semaglutide was initially created to help people manage type 2 diabetes, but was later adopted for weight loss as Ozempic. AI algorithms can even model clinical trials that simulate a wide range of individuals across genders, ethnic groups, comorbidities, and other factors that might influence a drug’s effects on an individual.

De Novo Drug Design
AI models are currently being used to generate and predict entirely new molecular structures that can interact with biological targets. Essentially, it attempts to create drug molecules from scratch rather than modify existing compounds. This approach to chemistry has been applied to atom-based, fragment-based, and reaction-based approaches for creating new structures, giving researchers multiple angles to approach a problem.

Precision Drug Development
Precision drugs are something of a holy grail for pharmaceutical companies, as they can treat a patient's condition with fewer side effects than a generic prescription. However, creating customized medication for a patient is obviously impractical under current drug development strategies. Generative AI can analyze multiple datasets, such as a patient's medical history, genetics, biobank studies, and more, to help design drugs tailored to their specific needs.

Benefits of Generative AI for Drug Discovery
Using generative AI for drug discovery isn’t simply a matter of using the newest, shiniest tool. It’s the key to developing better drugs more quickly and more cheaply.

Lower Costs
One of the most common complaints about healthcare, in general, and pharmaceuticals is the cost of medication. Much of that cost comes from the price of developing and testing iteration after iteration of the same drug, trying to amplify its positive effects while mitigating its downsides. Generative AI’s ability to sift through enormous amounts of data to find the right combination of molecules to produce a viable drug cuts down on the dead ends and wasted effort, lowering the cost of creating a new drug.

Faster Time to Market
With an average time of twelve to fifteen years to obtain a novel drug, too many patients are forced to wait for potentially life-saving treatment. Additionally, new medicines and treatments are needed to counter the rising threat of antibiotic-resistant bacteria, an issue that contributes to nearly 5 million deaths every year. This isn’t just a question of a pharmaceutical company’s profit margins, but a matter of life and death for patients around the world. Getting better drugs to the market faster, thanks to generative AI, can save lives.

Greater Treatment Accuracy
If you’ve ever seen an advertisement for a new pharmaceutical drug, you’ve probably seen the laundry list of side effects that they leave for the end of the ad. AI-designed drugs promise to be more accurate and refined, meaning they will have fewer adverse side effects as they work. Precision drugs tailored to each individual’s body can achieve greater effectiveness, leading to faster treatments and easier recovery.

Challenges for AI-Based Drug Discovery
Like any innovation, artificial intelligence comes with its hurdles to overcome. The most significant challenge is supporting and using these AI models effectively.

Avoiding AI Hallucinations
One of the most significant weaknesses of AI is that it can “hallucinate,” producing incorrect results or outcomes that are impossible to achieve. For example, it might suggest chemical compounds that are physically impossible to form under real-world conditions. The solution to this issue is to use AI models specifically trained on known, valid molecules and chemical reactions, such as Stanford Medicine’s SyntheMol AI. This helps ensure that the AI only suggests drugs that can be created.

Hardware Support
Modern AI models rely heavily on parallel processing, enabling them to analyze vast amounts of data simultaneously. However, parallel processing requires specialized computers equipped with the proper hardware, such as GPUs designed for this task. Healthcare and pharmaceutical groups interested in using generative AI need specialized tools, such as medical AI box PCs, to support it.

Cost of Implementation
As with any new tool, there is a price tag attached to AI. Both the hardware needed to run AI models and the licenses to use them can cost healthcare groups and pharmaceutical companies a pretty penny. One way to ameliorate this cost is to work with an original equipment manufacturer (OEM) for your hardware needs. These companies specialize in customizing products to meet the exact needs of the end-user, helping you get the performance and features you need without overpaying for things you don’t.

Embrace AI Drug Discovery with Cybernet Manufacturing
While there are challenges associated with its adoption, using generative AI for drug discovery could revolutionize the pharmaceutical industry, leading to better outcomes for patients around the world.

If your healthcare group or pharmaceutical company needs computer hardware capable of supporting AI models, contact Cybernet Manufacturing today. We offer AI computers equipped with the latest in NVIDIA GPUs that can handle a range of parallel processing tasks, and we can customize our products to better fit your specific requirements.